MOMETASONE TEVA 50 micrograms/dose, suspension for spraying nasal 120 doses
Active ingredients: Mometasone furoate, Mometasone furoate monohydrate
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for spraying120 dosesnasale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MOMETASONE TEVA 50 microgrammes/dose, suspension pour pulvérisation nasale
- Pharmaceutical form
- suspension pour pulvérisation
- Route of administration
- nasale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) de 120 dose(s) avec pompe polypropylène
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 4 Sept 2015
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68906169CIP72793950CIP133400927939501Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUROATE DE MOMÉTASONEsuspension | 50 microgrammes · une dose | FT |
| FUROATE DE MOMÉTASONE MONOHYDRATÉsuspension | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.